Recently, the outcomes of a 10-Year research comparing the clinical outcomes of the Indian stent “Yukon Choice PC” along with “Xience”—the market ruler—stents of the US-based Abbott showed that they were uniformly good. This result came after much debate over the quality of the stents made in India.
The study presented 2 Months ago also showed that another Indian stent—Supra Flex—was equally good as Xience. During the AHA’s (American Heart Association) scientific session held in Chicago, cardiologists from Germany conferred the results of a comprehensive follow-up of around 2,603 patients, who were randomized to healing with two latest-generation stents elite everolimus by Xience and sirolimus-eluting by Yukon Choice. The study disclosed in the AHA journal stated that there were no dissimilarities in the results amid the two latest generation stents. Dr. Ashok Seth—Chief of the Fortis Hospital Group Cardiology—asserted that these are the kind of researches we need. The randomized, extensive, and long-term studies should be done by Indian companies to set up their credibility globally, and each stent must be proven. He further added that the study also revealed that there was no differentiation between the stents with permanent polymeric coating and biodegradable polymeric coating that was based on the dispute that the stents with a coating of biodegradable polymers should fetch a higher price.
Recently, the AHA was also in news for updating cholesterol guidelines. More modified risk assessments and the latest cholesterol-lowering drug choices for people at the higher risk for cardiovascular disease are amid the major recommendations in the 2018 cholesterol guidelines. At any age, high cholesterol can increase an individual’s lifetime risk for heart problems and stroke. A healthy lifestyle is a primary step in prevention and action to lower that risk.